Tag: palbociclib

Genentech’s Phase 3 study of inavolisib in breast cancer reveals positive results

businessnewstoday- December 9, 2023

Genentech, part of the Roche Group, has presented compelling results from the Phase III INAVO120 study, evaluating the effectiveness of inavolisib in combination with palbociclib ... Read More

Roche’s inavolisib meets primary endpoint of PFS in Phase 3 breast cancer trial

businessnewstoday- December 6, 2023

Roche, a global leader in pharmaceuticals, announced positive results from its Phase III INAVO120 study, testing the investigational therapy inavolisib in combination with palbociclib (Ibrance) ... Read More

Zydus Lifesciences secures tentative FDA approval for Palbociclib Tablets

businessnewstoday- June 28, 2023

Zydus Lifesciences Limited, along with its subsidiaries and affiliates, has announced that it has been granted tentative approval by the US Food and Drug Administration ... Read More

Sun Pharma launches generic of breast cancer drug Palbociclib in India

businessnewstoday- January 11, 2023

Sun Pharmaceutical Industries (Sun Pharma) said that one of its fully-owned subsidiaries has launched the generic version of Pfizer-developed Palbociclib in India for patients with ... Read More

Olema Oncology to evaluate OP-1250, palbociclib combo in advanced breast cancer

pharmanewsdaily- November 15, 2020

Olema Oncology has entered into a clinical trial agreement with Pfizer to evaluate its small molecule OP-1250 in combination with the latter’s palbociclib (IBRANCE) in ... Read More

IBRANCE fails to meet primary endpoint in early breast cancer trial

pharmanewsdaily- October 11, 2020

Pfizer said that the phase 3 PENELOPE-B clinical trial of IBRANCE (palbociclib) in early breast cancer failed to meet its primary endpoint. The collaborative late-stage ... Read More

Ibrance FDA approval : Pfizer breast cancer drug approved for metastatic breast cancer in men

pharmanewsdaily- April 17, 2019

New Ibrance FDA approval : The US Food and Drug Administration (FDA) has extended the approval of Pfizer breast cancer drug Ibrance (palbociclib) to cover ... Read More